Chiusura precedente | 443,70 |
Aperto | 435,00 |
Denaro | N/D x N/D |
Lettera | N/D x N/D |
Min-Max giorno | 433,80 - 441,70 |
Intervallo di 52 settimane | 288,50 - 441,70 |
Volume | |
Media Volume | 473.710 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 0,45 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 429,87 |
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part of Novozymes’ commitment to driving innovation in biosolutions and promoting sustainable food choices. Copenhagen – September 28: Today marks an important milestone in the evolution of plant-based meat innovation with the lau
The two companies have signed a joint development and commercialization agreement to launch feed additive Ablacto+. The game changing biosolution uses binding proteins to stabilize the gut of piglets, thereby reducing the need for antibiotic consumption. Copenhagen, Denmark – 4 September 2023. Novozymes and the Danish industrial biotech company, Bactolife, have signed a joint development and commercialization agreement to finish development and launch the biosolution Ablacto+. The promising prod
After the first half of 2023, Novozymes sees overall stability in a volatile environment and delivers 3% organic sales growth. Following destocking and lower consumer demand, the organic full-year sales growth outlook is slightly narrowed from 4-7% to 4-6%. Growth is expected to be driven mainly by pricing. COPENHAGEN, Denmark – August 9, 2023. Novozymes delivers 3% organic sales growth, an EBIT-margin of 25% before special items, and ROIC including goodwill of 17% before special items in the fi